Jubilant Pharmova Limited Financial Ratios
JUBLPHARMA · Healthcare · Current price ₹933.5
P/E ratio
37.1x
P/B ratio
2.3x
ROE
5.6%
ROCE
7.7%
Debt / Equity
0.51
Dividend yield
0.5%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 37.1x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 2.3x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 5.6% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 7.7% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.51 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Jubilant Pharmova Limited's latest numbers.
Jubilant Pharmova Limited profitability
Jubilant Pharmova Limited generates a return on equity of 5.6% and a return on capital employed of 7.7%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.51 and a P/E of 37.1x, Jubilant Pharmova Limited is moderately leveraged. Our overall business-quality score for the company is 3.8 / 10.
Understand the ratios
More on Jubilant Pharmova Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.